Triple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancer and is characterized by the absence of expression of both estrogen (ER) and progesterone (PgR) receptors as well as of human epidermal growth factor receptor 2 (HER2). This evidence concerns the gene ERBB2 and breast carcinoma.